Predictive Oncology Announces Planned European Launch of its ChemoFx® Treatment Selection Marker and Tumor Profiling Assay

Stock Information for Revance Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Revance Therapeutics Inc.

Predictive Oncology Develops Novel Approach to Identifying Clinically Viable Abandoned Drugs
Renovaro Provides Update to Definitive Agreement with Predictive Oncology
Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update
Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary
Predictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries
Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology
Predictive Oncology Moves to Finalize Definitive Merger Agreement With Renovaro Biosciences
Predictive Oncology Closes Registered Direct Offering

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.